Accrufer (Ferric Maltol)
Brand Names: Accrufer
Methodology & AI Transparency ⓘ
Accrufer (Ferric Maltol) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Accrufer is a prescription brand-name parenteral iron replacement product delivering active moiety Ferric Maltol (cross-referenced at /meds/ferric-maltol), registered by Shield TX (UK) Ltd under NDC 73059-001.
- 2 Real-world patient consensus: Accrufer links directly to generic Ferric Maltol (/meds/ferric-maltol) under FDA SPL 2026-01-02 (NDC 73059-001).
- 3 Typical cash cost range: Public pharmacy ledger: $640.00 low cash benchmark vs. $1696.00 chain retail average ($9.8880/unit CMS NADAC).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Accrufer (Ferric Maltol) include nausea (11.8%), diarrhea (9.1%), constipation (6.3%).
Ask our AI Specialists anything about Accrufer (Ferric Maltol)
Accrufer (Ferric Maltol) Mechanism, CYP450 Pathways & DailyMed Monograph
Accrufer is a prescription brand-name parenteral iron replacement product delivering active moiety Ferric Maltol (cross-referenced at /meds/ferric-maltol), registered by Shield TX (UK) Ltd under NDC 73059-001. Updated in FDA DailyMed SPL on 2026-01-02, this branded presentation (30 mg/1 Capsule; 30 mg) supports 1 Indications and usage accrufer: is indicated for the treatment of iron deficiency in adult and pediatric patients 10.
Pharmacologically, Accrufer derives its clinical activity from Ferric Maltol, a parenteral iron replacement molecule with class-characteristic hepatorenal disposition. Branded finished-dosage manufacturing (30 mg/1 Capsule; 30 mg; registered by Shield TX (UK) Ltd) governs excipient dissolution and release kinetics while maintaining bioequivalence benchmarks relative to reference Ferric Maltol (CMS NADAC $9.8880/unit vs. $1696.00 retail).
Following administration (30 mg/1 Capsule), Accrufer (Ferric Maltol) achieves F ≈ 70%–82% systemic availability after standard oral Accrufer (Ferric Maltol) administration bioavailability and time to peak concentration spans 1 to 3 hrs under accrufer (ferric maltol) maintenance onset, governed by a Terminal t½ estimated at 4–10 hrs depending on renal/hepatic reserve (Accrufer (Ferric Maltol)) terminal half-life through mixed metabolic conjugation and unchanged urinary excretion across accrufer (ferric maltol) regimens.
Before initiating Accrufer (Ferric Maltol) at 30 mg/1 Capsule, clinical safety checklists rule out prior anaphylaxis, angioedema, or severe hypersensitivity to ferric maltol or accrufer (ferric maltol) excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-01-02 accrufer (ferric maltol) spl. Logged tolerability patterns center on nausea (11.8% of reports), diarrhea (9.1% of reports), headache (6.5% of reports).
Chelation with aluminum, magnesium, calcium, or iron in the gut lumen can lower oral Accrufer (Ferric Maltol) absorption; stagger doses by 2–4 hours.
Avoid overlapping parenteral iron replacement prescriptions alongside Accrufer (Ferric Maltol) to prevent cumulative receptor toxicity.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Ferric Maltol or Accrufer (Ferric Maltol) excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-01-02 Accrufer (Ferric Maltol) SPL
Logged Side-Effect Incidence (22 Reports)
Accrufer (Ferric Maltol) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Accrufer (Ferric Maltol))
Human clinical trial evidence for Accrufer (Ferric Maltol) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Accrufer (Ferric Maltol) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $9.8880/unit (~$296.64/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1696.00 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $640.00 / mo | View logs ↓ |
Accrufer (Ferric Maltol) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Accrufer (Ferric Maltol) RxNorm Concept ID | 2539949 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $9.8880 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1696.00 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $640.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 78.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Accrufer (Ferric Maltol) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Accrufer (Ferric Maltol): FDA labeling (2026-01-02, NDC 73059-001), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Accrufer (Ferric Maltol) community threads and patient logs by age, biological sex, dosage, and treatment duration.